Carmustine

Carmustine (BiCNU) is a cell-cycle phase nonspecific alkylating antineoplastic agent with ED50 ranging from 5.0 µM to 11.9 µM. It is used in the treatment of several types of brain cancer (including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma), multiple myeloma and lymphoma (Hodgkin’s and non-Hodgkin). In a study, three lines with O6-AGT activity below 25 fmol/mg protein had carmustine ED50 values ranging from 5.0 µM to 11.9 µM.